HDR Gateway logo
HDR Gateway logo

Bookmarks

Evaluation of de novo diabetes or diabetes worsening in metastatic castration resistant prostate cancer patients treated with abiraterone acetate compared with enzalutamide in England.

Safe People

Organisation name

Astellas Pharma Europe Ltd

Organisation sector

Commercial

Safe Projects

Project ID

CPRD 20_0000234 (ODR2122_2746)

Lay summary

Evaluation of de novo diabetes or diabetes worsening in metastatic castration resistant prostate cancer patients treated with abiraterone acetate compared with enzalutamide in England.

Latest approval date

22/02/2022

Safe Data

Dataset(s) name